Table 3.

Rates of ARIA and Mean CDR-SB Change According to APOE Genotype.

	Lecanemab			Placebo
	APOE ε4 status			APOE ε4 status
	None N = 278	Heterozygote N = 479	Homozygote N = 141	None N = 286	Heterozygote N = 478	Homozygote N = 133
ARIA-E	5.4 %	10.9 %	32.6 %	0.3 %	1.9 %	3.8 %
Symptomatic ARIA-E	1.4 %	1.7 %	9.2 %	0 %	0 %	0 %
ARIA-H	11.9 %	14.0 %	39.0 %	4.2 %	8.6 %	21.1 %
CDR-SB	−0.76 (−1.16, −0.35)	−0.51 (−0.79, −0.23)	+0.28 (−0.35, +0.88)	Ref	Ref	Ref

	Donanemab			Placebo
	APOE ε4 status			APOE ε4 status
	None N = 255	Heterozygote N = 595	Homozygote N = 143	None N = 250	Heterozygote N = 474	Homozygote N = 146
ARIA-E	15.7 %	22.8 %	40.6 %	0.8 %	1.9 %	3.4 %
Serious ARIA-E	0.4 %	1.8 %	2.8 %	0 %	0 %	0 %
ARIA-H	18.8 %	32.4 %	50.3 %	11.2 %	12.0 %	20.5 %
Serious ARIA-H	0.4 %	0.2 %	1.4 %	0 %	0 %	0 %
CDR-SB	−0.76 (−1.21, −0.31)	−0.73 (−1.06, −0.40)	−0.41 (−1.00, 0.19)	Ref	Ref	Ref

ARIA risk and clinical efficacy according to APOE genotype in the CLARITY-AD (lecanemab) and TRAILBLAZER-ALZ 2 (donanemab) trials. Values are percent (for ARIA) or, for CDR-SB, the adjusted mean difference from placebo (Ref). In TRAILBLAZER-ALZ 2, only the subset of symptomatic ARIA that was considered “serious” (i.e., resulted in death, was life-threatening, required hospitalization, or caused persistent disability) was reported by APOE status. For ease of comparison, change in CDR-SB is shown for both trials; the interaction between APOE status and iADRS (the primary outcome in TRAILBLAZER-ALZ 2) was similar. For TRAILBLAZER-ALZ 2, results are shown for the combined tau group.